US Patent

US9084802 — Tetracycline compositions

Method of Use · Assigned to Rempex Pharmaceuticals Inc · Expires 2031-05-12 · 5y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions, including pharmaceutical compositions, of tetracycline with improved stability and solubility.

USPTO Abstract

The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.

Drugs covered by this patent

minocycline-hydrochloride (MINOCYCLINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-282`	—	minocycline-hydrochloride

Patent Metadata

Patent number: US9084802
Jurisdiction: US
Classification: Method of Use
Expires: 2031-05-12
Drug substance claim: No
Drug product claim: No
Assignee: Rempex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.